+91 9891296838 / 9811747774
Obeticholic acid (abbreviated to OCA, trade name Ocaliva), is a semi-synthetic bile acid analogue which has the chemical structure 6α-ethyl-chenodeoxycholic acid. It is used as a drug to treat primary biliary cholangitis, and is undergoing development for several other liver diseases and related disorders
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of Obeticholic acid brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the medicine and its cost price in India.
The order for Obeticholic acid will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Ocaliva (Obeticholic acid)
Generic Name: Obeticholic acid
Tablets: 5 mg, 10 mg
60/4 1st Floor, T&T Building, Indian Oil Complex,
Yusuf Sarai, New Delhi, Delhi 110016
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand Braftovi (Encorafenib) on prescription and Import License in Patient's Name only.
For overseas patients, obeticholic acid can be made available in Send your enquiry to find Braftovi (Encorafenib) in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
FDA OKs Intercept’s NDA for obeticholic acid; shares up 5% premarket For More Details
Intercept Pharma Shares Rise on FDA Acceptance of NDA for Liver Fibrosis Treatment. For More Details